Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Can Launch Neupogen Biosimilar One Month Before Patent Expiration

This article was originally published in The Pink Sheet Daily

Executive Summary

Under a settlement with Amgen, Teva can begin selling its G-CSF product in November 2013; the launch may be sooner if a third party launches or wins an infringement suit.

You may also be interested in...



Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain

Teva is the first company to get FDA approval of a version of Amgen’s Neupogen; one biosimilar expert questions why Teva did not switch its BLA to a biosimilar application when that pathway became available.

Biosimilar Road Bump: Teva Filgrastim's Complete Response Shows Even Full BLAs Can Stumble

FDA issued a complete response letter requesting "several items" from Teva to finish review of its biological license application.

Roche Can Launch Mircera 10 Months Before Amgen's EPO Patent Expires

Amgen inked a license agreement with Roche in settling its patent infringement suit.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel